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Immunizations—
Not Just For Kids
By Harrison Bloom,M.D.
Introduction
Immunizations/vaccinations are beneficial for most people of all ages. Yet
the mistaken belief persists that, with the exception of the flu vaccine,
children should be the primary recipients of this important area of primary
disease prevention.
In fact, older persons require immunization as well. As people grow older
they become increasingly vulnerable to a variety of illnesses, and, as informal
caregivers of young children, grandparents need to be sensitive to their role
in preventing the spread of contagious diseases to the young.
Vaccines can prevent the onset and/or consequences of these serious, often
deadly, diseases:
Diseases and Vaccines
Influenza (Flu)
What is influenza?
Influenza is a contagious viral infection of the nose, throat, and lungs that
usually occurs in the winter. Viral and/or bacterial pneumonia can be caused
or facilitated by influenza infection. It differs from other common respiratory
infections by virtue of its ability to cause severe disease that can result in sig-
nificant sickness, hospitalization and death.
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• influenza
• pneumococcal disease
• tetanus-diphtheria-pertussis (Tdap)
• chickenpox and shingles (varicella
and varicella-zoster)
• meningococcal disease
• measles-mumps-rubella (MMR)
• human papillomavirus (HPV)
• hepatitis A and hepatitis B
• polio
Who is most vulnerable?
On average 35,000 people in the United States die
from influenza and its complications each year. More
than 90 percent are persons 65 and older. The flu can
worsen the condition of people with chronic lung dis-
ease, heart disease, and diabetes.
All persons over age 50, residents of nursing homes
and other chronic care facilities, health care workers
(to prevent transmission to others within a facility),
and those with underlying chronic medical conditions
should be immunized every year.
It is especially important that any person over age 50
who is admitted to an acute care setting between
September and March receive a vaccination. In nursing
home residents, the vaccine is most effective in prevent-
ing severe illness, secondary complications, and death.
National data indicate that 65 percent of those over 65
get vaccinated. The Centers for Disease Control
(CDC) and the Advisory Committee on Immunization
Practices (ACIP) now recommend that all adults begin
receiving annual influenza immunization at age 50. In
fact, current guidelines recommend annual flu vaccine
for all adults who want to reduce the risk of becoming
ill with influenza or of transmitting it to others.
What is the financial cost to society of influenza?
During the 1990s, an average of 200,000 people each
year were hospitalized because of flu-associated com-
plications. More than $3 billion is the estimated
direct hospitalization cost of a severe flu epidemic.
When is the best time to get a flu shot?
Vaccination is best administered in October and
November of each year and should continue through
December (and beyond) if flu season arrives later than
usual. Influenza viruses change from year to year, and
immunity, especially in older persons, declines within a
year after vaccination, making it necessary for everyone
to be immunized yearly. A nasal spray vaccine is available,
but it has not been approved for persons age 50 and older.
Pneumococcal Disease
What is pneumococcal disease?
Pneumococcal disease is a bacterial infection caused
by Streptococcus pneumoniae. These bacteria can cause
pneumonia when they invade the lungs. In fact, the
pneumococcal bacteria are the leading cause of pneu-
monia. When they invade the bloodstream (bacteremia)
and/or tissues surrounding the brain and spinal cord
(meningitis), the disease can be severe, sometimes lead-
ing to infections of the bloodstream and to death.
Fever, cough, chest pain, and shortness of breath are
the typical symptoms of pneumonia. Symptoms of
meningitis may include fever, stiff neck, disorienta-
tion and mental confusion, and photophobia (visual
sensitivity to light). Bacteremia symptoms include
some of the same as with pneumonia and meningitis,
as well as joint pain and shaking chills.
Who is most vulnerable?
There are approximately 40,000 cases of invasive pneu-
mococcal disease each year in the United States. In the
general population there are 15 to 30 cases reported
out of 100,000. In people over age 65, that number
increases to 50–83 out of 100,000. Case fatality rate for
pneumococcal bacteremia among older adults is 30 to
40 percent. The ACIP and the American College of
Physicians (ACP) recommend that everyone over 65
receive the vaccine. Reimmunization is recommended
for high-risk older individuals who received their first
dose more than five years previously.
The pneumococcal vaccine
The pneumococcal vaccine was first released in the
1940s, but was withdrawn when penicillin and
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Although controversy exists over the degree to
which influenza vaccine protects adults over 65,
annual vaccination for all adults over age 50 is
still recommended.
sulfonamide drugs became widely available. It was
relicensed in 1977 when drug-resistant strains began
to make their appearance. The vaccine available today
includes over 95 percent of multidrug-resistant,
invasive strains.
The vaccine can be given at any time of the year, and
it can be administered at the same time (in the oppo-
site arm) as flu vaccine.
It is recommended that people in the following cate-
gories receive the pneumococcus vaccine:
• People over age 65
• People with underlying chronic illness
(e.g., heart disease, lung disease, diabetes)
• People with a weakened immune system
(e.g., HIV infection, chronic renal failure)
• Residents of nursing homes and other long-term
care facilities
• Alaska natives and some Native American tribes
It is sometimes recommended that older persons
receive a second dose after a number of years.
Tetanus, Diphtheria, Pertussis
Tdap is a single vaccine to protect against all three.
What is tetanus?
Tetanus is a bacterial toxin that attacks the nervous
system and is commonly found in soil, dust, and
manure. Known colloquially as “lockjaw,” this disease
is usually contracted through a wound or cut contami-
nated with the tetanus bacteria. Symptoms include
muscular stiffness in the jaw (lockjaw), then neck
stiffness, trouble swallowing, abdominal muscle
rigidity, generalized spasms, fever, and sweating.
Who is vulnerable?
Although 50 or fewer cases of tetanus occur each year
in the United States, more than 15 percent are fatal
and more likely to affect diabetics and persons over
60. Almost all reported cases occur in people who
never had the primary series of immunizations or
those who received the primary series but didn’t
follow up with a booster shot in ten years.
What is diphtheria?
Diphtheria is a potentially serious bacterial disease
that is spread from person to person by inhaling
droplets containing the diphtheria bacteria. The
tonsils, throat, nose, and skin are usually affected.
The infection can cause a “membrane” to form over
the throat, causing breathing problems. If untreated,
heart failure, paralysis, and even death can result
(mortality is close to 10 percent). The main symptoms
include severe sore throat, fever, enlarged lymph
nodes, and/or painful red and swollen skin lesions.
Who is vulnerable?
Most cases of diphtheria occur among persons who
are unvaccinated or inadequately vaccinated.
What is pertussis?
Pertussis (whooping cough) is caused by the organism
Bordetella pertussis. A potentially serious disease that
spreads easily from person to person, its hallmark is
coughing spells so severe that breathing, eating, and
sleeping are difficult. Coughing can be severe enough
to fracture ribs, and pneumonia and hospitalization
can occur. Interestingly, adults rarely manifest the
classic “whoop” (the sound made while gasping for
breath during a bad coughing spell).
Who is vulnerable?
Grandparents, parents, and siblings can spread pertus-
sis to infants not yet fully vaccinated even before
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A single dose of pneumococcus vaccine is
protective against 23 different types of
Streptococcus pneumoniae bacteria that
cause most cases of pneumococcal disease.
symptoms appear. The disease is increasing in preva-
lence in the United States. Because early symptoms
may mimic the common cold or bronchitis, the diag-
nosis is frequently difficult to make or delayed. Adults
and adolescents can spread pertussis to infants not
yet fully vaccinated, even before symptoms appear.
Parents, grandparents and siblings are often the
source of pertussis in babies.
Currently the CDC recommends that adults ages 19
to 64 receive a single dose of Tdap in place of the Td
(tetanus-diphtheria) booster previously recommended
for all adults. However, they recommend that the Td
booster shots be given to individuals age 65 and older.
Recommendations for additional specific adult popu-
lations include those who have or anticipate having
close contact with an infant less than 1 year of age,
health care workers who have direct patient contact,
and women who have just given birth (before dis-
charge from the hospital or birthing center).
Varicella-zoster (Shingles)
What is shingles?
Zoster, which is also known as shingles, is common
in people over age 50, with an estimated 500,000 to
1 million cases diagnosed in the United States each
year. The virus, the same one that causes chickenpox,
lies dormant for years in nerves (in those who had
chickenpox in the past, usually as children) and typi-
cally becomes reactivated in people during normal
aging, especially in those whose immune systems have
been weakened by cancers, HIV infection, or treat-
ment with immunosuppressive drugs. The rash is
often painful and blistering, occurring on the trunk
(one side of the body only) or the face. Although the
pain and rash usually resolves within weeks, it is often
followed by an excruciatingly painful and long-lasting
condition known as postherpetic neuralgia. This con-
dition is usually very difficult to treat and can make
an individual’s life miserable.
Who should be vaccinated?
In October 2006, the ACIP recommended a single
dose of zoster vaccine for adults 60 years of age or
older. They further noted that most older adults
have been infected or exposed to chickenpox, and it
is not necessary to screen older people to determine
whether there is a history of chickenpox for routine
vaccination.
The zoster vaccine was licensed by the FDA in May
2006. Large studies, with a median follow-up of
3.1 years, showed a 51 percent relative-risk reduction
for zoster and a 67 percent relative-risk reduction for
postherpetic neuralgia. Efficacy was highest in those
60 to 69, declining with increasing age. The vaccine is
considered safe, but it is not yet known how long the
protection lasts. This vaccine is the first to be covered
under Part D Medicare, rather than Part B (which
covers flu and pneumococcal vaccines). Cost for the
vaccine is $150 to $200.
Because the vaccine is new and long-term effects
are not yet known, an individual should speak with
her/his physician regarding the advisability of getting
the vaccine.
Other diseases for which vaccines should be
considered in susceptible adults:
Varicella (Chickenpox)
What is chickenpox?
Chickenpox is caused by the varicella virus. Very con-
tagious and easily spread from person to person,
chickenpox is characterized by a total body rash of
250 to 500 itchy blisters, as well as fever, fatigue, and
sore throat.
Who is vulnerable?
Although not usually severe, the risk of hospitalization
and death is greater in adolescents and adults than
in children. Less than 5 percent of adults are susceptible
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to infection with the varicella virus, younger adults being
more susceptible than older adults. Immunocompromised
individuals are particularly at risk for serious illness and
complications if they contract chickenpox.
The vaccine is recommended for all susceptible adults
(those who never had chickenpox) with a second
catch-up dose for adults who previously received only
one dose. Infrequently persons previously vaccinated
can develop chickenpox, but the disease is usually mild
and the rash doesn’t evolve into blisters.
Measles, Mumps, Rubella
MMR is a single vaccine to protect against all three.
Measles
Of the 66 confirmed cases of measles in the United
States reported in 2005, nearly 35 percent were in peo-
ple over age 20. Serious lung and middle-ear infections,
as well as severe diarrhea and brain inflammation, can
occur. On a global basis, almost half a million deaths
occur annually from 30 million infected individuals.
Mumps
Serious complications of mumps occur more frequently
among adults than children.Women contracting
mumps during the first trimester of pregnancy are at
risk for spontaneous abortion. MMR vaccine is indi-
cated in susceptible individuals.
Rubella (German Measles)
Rubella during pregnancy can lead to serious birth
defects in the baby including deafness, cataracts, heart
defects, mental retardation, and liver and spleen damage.
Meningococcal Disease
What is meningococcal disease?
A very serious and potentially deadly bacterial infection
causing meningitis, bloodstream infection, and, less fre-
quently, pneumonia or arthritis, meningococcal disease is
easily spread through sneezing, coughing, or by direct
contact such as kissing. Even if treated appropriately, 10
percent of those infected die, and 20 percent develop per-
manent disabilities including brain damage, hearing loss,
and limb amputations. Almost 3,000 persons contract
meningococcal disease each year in the United States.
Who is vulnerable?
In adults, the vaccine is recommended for college
freshmen living in dormitories and individuals up to
age 55, based upon their living situation (e.g., military
personnel), travel plans, or underlying medical condi-
tions. For those over age 55, a version of the vaccine,
a polysaccharide vaccine, is available.
Human Papillomavirus (HPV)
What is HPV?
HPV is the most common sexually transmitted infec-
tion in the United States. About 6 million men and
women become infected each year, and more than
20 million are infected in 2007.
Who is vulnerable?
It is most prevalent in persons in their late teens and
twenties. At least 80 percent of sexually active women
will have become infected by age 50. HPV causes
almost 100 percent of cervical cancer in women and
contributes to the development of other cancers that
can affect both men and women. In the United States,
9,700 women are diagnosed with cervical cancer, and
3,700 deaths occur from cervical cancer yearly. The
vaccine should ideally be given to girls or women
before the onset of sexual activity and is currently
recommended for all previously unvaccinated women
through age 26.
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For travel to countries where diseases no longer
prevalent in the United States are still common,
check the Centers for Disease Control website
(www.cdc.gov/travel/) for recommendations two
to three months before departure.
Hepatitis A and Hepatitis B
What is hepatitis A?
Hepatitis A is a viral disease of the liver that is easily
spread by a variety of routes. Symptoms and their
severity can vary significantly among infected individ-
uals, but older persons usually have more severe symp-
toms than children. Once contracted, there is no
specific treatment. About 10 to 20 percent of people
with hepatitis A require hospitalization.
Who is vulnerable?
A vaccine is recommended primarily for travelers to
countries where the disease is common. It is also recom-
mended for individuals with specific medical conditions.
What is hepatitis B?
Hepatitis B (HBV) is a very serious viral disease of the
liver. It can result in lifelong infection that increases the
risk of developing chronic liver disease, including cirrho-
sis and liver cancer. An estimated 1.25 million people in
the United States have chronic HBV infection, and
about 5,000 die from its complications yearly. It is classi-
fied as a sexually transmitted disease and is 100 times
more infectious than HIV, the virus that causes AIDS.
Who is vulnerable?
The vaccine is effective and safe. The list of persons
for whom the vaccine is recommended is long, but
any adult wishing to obtain immunity may receive it.
Avian Flu Virus (Bird Flu)
At the present time there is no vaccine to protect
against this highly pathogenic virus found in many
bird populations. Its presence in humans has thus far
been very limited, but all experts agree that this virus,
or a variant, could possibly cause a pandemic. The
World Health Organization has issued pharmacologic
guidelines addressing prophylaxis and treatment for
patients infected with the avian flu virus, and it is
constantly monitoring all developments in this area.
Conclusion
Some people are fearful that a vaccine will give them
the very disease it is supposed to prevent. Actually, the
potential risks associated with contracting the diseases
prevented by the vaccines are much greater than the
potential risks from the vaccines themselves.Mild side
effects are not uncommon and usually include a sore arm
or low-grade fever for a day or two, but the risk that seri-
ous problems will occur following vaccination is minimal.
Most family physicians and internists, hospital clinics,
city and county health departments, and many pharma-
cies administer influenza, pneumococcal, and hepatitis
A and hepatitis B vaccines. Sometimes special vaccina-
tion clinics are held in shopping malls, senior centers,
and other community settings. Medicare Part B covers
the cost of influenza and pneumococcal vaccinations.
Private insurance plans vary in their rates of coverage.
In 2003, the American Journal of Medicine reported
that 100 percent of vaccinated patients said their
physician recommended the vaccine versus 63 percent
of unvaccinated patients. Busy health care providers
may neglect to address the need for immunizations or
may suggest only that patients receive a flu shot. All
adults must be actively involved in their health care
and assure they receive appropriate immunizations.
Finally, all adults should keep a permanent immuniza-
tion record, both to ensure that protection has been
provided against vaccine-preventable diseases and also
to prevent needless revaccination if there is a change in
a health care provider or during a health emergency.
Harrison Bloom, M.D., a geriatrician, is director of the
ILC-USA Clinical Education Consultation Services.
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Bottom Line: Immunizations are among the
safest, most inexpensive, most cost-effective,
and accessible preventive measures available
for adults as well as children.
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Immunization Record Card. This adult immunization card is designed to facilitate personal record-keeping of
all immunizations. It can be cut out and folded to fit easily in a wallet. Take this card to every health visit and
have your health care provider keep it and your immunizations up to date.
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